Health News Archive - May 28, 2009
AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP). Orphan Drug Designation for AIP entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-021 if this product candidate is the first new drug with a major medical benefit receiving marketing approval for the European Union.
- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer - New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen - Phase II data show potential of Glivec(R) in treating patients with advanced KIT-mutated melanoma; other Novartis data on advanced melanoma also presented EAST HANOVER, N.J., May 28 /PRNewswire/ -- Novartis announced today that data on more than 15 compounds in its robust oncology portfolio will be included at the 2009 American Society of Clinical Oncology (ASCO) annual meeting.
Site to Provide Glucotrace (Fluorodeoxyglucose) for Use in Earlier Detection of Disease and Therapy Management OTTAWA and FLEURUS, Belgium, May 28 /PRNewswire-FirstCall/ - MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced the opening of a facility in Fleurus, Belgium for the production of Glucotrace (Fluorodeoxyglucose), a radiopharmaceutical used in positron emission tomography (PET) imaging. PET imaging produces a three-dimensional image, or picture, of functional processes in the body, such as brain activity, and is a highly accurate and effective method of diagnosing disease and managing patient therapy.
BOSTON, May 28 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the Goldman Sachs 30th Annual Global Healthcare Conference in New York.
Sodexo is first food service company to sign on to Alliance's Guidelines GAITHERSBURG, Md.
- Update from Advanced Breast Cancer and Melanoma Studies - Conference Call to be Hosted on Wednesday, June 3, 2009 at 11:00 am BRANFORD, Conn., May 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today announced plans for three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
Proteon also receives orphan drug designation for its lead product candidate, PRT-201 WALTHAM, Mass., May 28 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has completed a second closing of its Series B equity financing, securing an additional $12 million and increasing the total equity capital raised in this round to $50 million.
SAN MATEOâ€š Calif.â€š May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.
Company seeking endorsement of programs to reduce the risk of E. coli O157 contamination of food and water BELLEVILLE, ON, May 28 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc.
TURKU, Finland, May 28 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally. The open-label, dose-escalating study is designed to evaluate the safety, tolerability and pharmacokinetics of the locally administered (into the bladder) product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer and it is expected to be well tolerated. "We are pleased to advance to clinical testing with the ProtoCure instillation solution," says Lasse Leino, CEO of BioCis Pharma.
- A political dynamiter.